Browse Category

Biotech Stocks News 10 December 2025 - 18 December 2025

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is back in the spotlight on Tuesday, December 16, 2025—not because the story suddenly got simpler, but because it’s at the intersection of three things the market obsessively prices every day: regulatory risk, clinical evidence,
Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is back on traders’ radars on December 16, 2025, after a sharp, high-volume move that has pushed the clinical-stage biotech into “crowded trade” territory—where catalysts, liquidity, and sentiment can matter as much as fundamentals. As
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class”
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences, Inc. (NYSE: RCUS) is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences Corp. (NASDAQ: AVXL) is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex (also known as blarcamesine / ANAVEX®2-73) in Alzheimer’s disease—an outcome that investors had been
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

As Wall Street digests a fresh Federal Reserve rate cut and growing worries about an AI spending bubble, today’s U.S. stock tape is dominated by dramatic downside moves. From Oracle’s double‑digit plunge to biotech blow‑ups and reverse‑split micro‑caps, December 11,
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise
1 2 3
Go toTop